May, 2024
May 2024
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Tanja Obradovic: What can we expect from antibody-drug conjugates (ADCs) in advanced ovarian cancer beyond Mirvetuximab?
Apr 17, 2024, 11:33

Tanja Obradovic: What can we expect from antibody-drug conjugates (ADCs) in advanced ovarian cancer beyond Mirvetuximab?

Tanja Obradovic,

“What can we expect from antibody-drug conjugates (ADCs) in advanced ovarian cancer beyond Mirvetuximab? Patients may soon have new treatment options since among currently ongoing 58 PhaseII/III or Phase III trials there are 4 ADC testing studies to highlight: REJOICE-Ovarian 1 (just dosed first patient on April 3rd), REFRaMe-01, GLORIOSA, and IMGN853-301.

First one on the horizon to reach finalization in the 1stQ this year is IMGN853 (platinum resistant patients, trial of Mirvetuximab in Chinese patients) followed by REFRaMe-01 trial (also platinum resistant patients, global trial) expected to finish 4Q 2025.

Luveltamab Tazevibulin has potential to be the first ADC to treat ovarian cancer patients with low-to- medium folate receptor-α (FolRα) expression (received ‘Fast Track Designation’ by FDA last year).

Good initial results from REFRaMe-01 trial have been just recently reported by Sutro Biopharma Incorporated (link below). Community is eagerly awaiting any further updates as positive outcome of Luveltamab Tazevibulin in REFRaMe-01 trial could double currently eligible platinum resistant patient population considering FolRα-targeting because Mirvetuximab requires high Folate receptor expression (over 75% of viable tumor cells with moderate to high staining).

Although aimed only for ‘high’ Folate receptor population, Mirvetuximab may still broaden current use based on exploration in GLORIOSA trial where Mirvetuximab is tested in the maintenance setting for the platinum sensitive patients.

Novel development is within REJOICE-Ovarian01 trial where Raludotatug Deruxtecan is potentially first-in-class Cadherin-6 (CDH-6) directed ADC and is tested in platinum resistant ovarian cancer patients including those that may have progressed on Mirvetuximab. Therefore, Raludotatug deruxtecan may potentially offer critical new treatment option within the current and future landscape re-shaped by Folate-receptor directed ADCs.”

Additional information.
Source: Tanja Obradovic/LinkedIn


About OncoDaily

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”